Longitudinal clinical and preclinical studies identify hetrombopag as a potent chelator for systemic iron overload - PubMed
a day ago
- #Iron Overload
- #Ferroptosis
- #Hetrombopag
- Iron overload (IO) is a pathological condition caused by excessive iron accumulation, leading to systemic functional impairment.
- Iron chelation therapy (ICT) is the standard treatment for transfusion-related IO, but current chelators have limitations like toxicity and administration challenges.
- Hetrombopag (HPAG), an oral thrombopoietin receptor agonist, has an iron-scavenging moiety independent of its primary activity.
- Clinical and preclinical studies show HPAG is effective as both a prophylactic and therapeutic agent for systemic IO.
- HPAG acts as a ferroptosis inhibitor by reducing toxic iron accumulation and suppressing iron-induced lipid peroxidation.
- The findings suggest targeting ferroptosis is a novel therapeutic strategy for systemic IO.